Upsher Smith Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UPSHER SMITH LABS, and what generic alternatives to UPSHER SMITH LABS drugs are available?
UPSHER SMITH LABS has eighty-nine approved drugs.
There are eight US patents protecting UPSHER SMITH LABS drugs.
There are seventeen patent family members on UPSHER SMITH LABS drugs in ten countries and one hundred and thirty-four supplementary protection certificates in thirteen countries.
Summary for Upsher Smith Labs
International Patents: | 17 |
US Patents: | 8 |
Tradenames: | 69 |
Ingredients: | 63 |
NDAs: | 89 |
Drugs and US Patents for Upsher Smith Labs
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upsher Smith Labs | CIMETIDINE | cimetidine | TABLET;ORAL | 074506-001 | Jan 24, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Upsher Smith Labs | PREVALITE | cholestyramine | POWDER;ORAL | 073263-001 | Feb 22, 1996 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Upsher Smith Labs | QUDEXY XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 205122-003 | Mar 11, 2014 | AB2 | RX | Yes | No | 8,652,527 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Upsher Smith Labs | CIMETIDINE | cimetidine | TABLET;ORAL | 074506-002 | Jan 24, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Upsher Smith Labs | QUDEXY XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 205122-003 | Mar 11, 2014 | AB2 | RX | Yes | No | 10,363,224 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-007 | Oct 2, 2003 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Upsher Smith Labs
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE43580 | ⤷ Try a Trial |
Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | 6,440,392 | ⤷ Try a Trial |
Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE40812 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UPSHER SMITH LABS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Nasal Spray | 200 IU/spray | ➤ Subscribe | 2006-03-29 |
➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2015-12-24 |
International Patents for Upsher Smith Labs Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1223852 | ⤷ Try a Trial |
Brazil | 112015022434 | ⤷ Try a Trial |
European Patent Office | 2968177 | ⤷ Try a Trial |
Canada | 2857286 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2014143380 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2015089289 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Upsher Smith Labs Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1856135 | 2020/017 | Ireland | ⤷ Try a Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113 |
1409467 | 244 4-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: ELIGLUSTAT (VO FORME TARTRATU); REGISTRATION NO/DATE: EU/1/14/974 20150121 |
0513917 | C980018 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001-002 19980318 |
2924034 | CR 2019 00024 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH LAMIVUDINE AND IN COMBINATION WITH TENOFOVIR DISOPROXIL FUMARATE; REG. NO/DATE: EU/1/18/1333 20181126 |
0186405 | SPC/GB00/021 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316 |
0454511 | 99C0009 | Belgium | ⤷ Try a Trial | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.